Camrelizumab plus apatinib
KY2019-SHR-APA-ZJU
Phase 2 small_molecule active
Quick answer
Camrelizumab plus apatinib for Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active